BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, was recognized by the Healthcare Businesswomen’s Association (HBA) as a 2021 Luminary. This title honors the 30-plus years of Dr. Eisenberg’s career, which she has dedicated to innovations in healthcare and science, as well as her efforts in the advancement of women in the industry.
“I am honored to have been recognized as an HBA Luminary,” said Dr. Eisenberg. “Throughout my career, I have been fortunate enough to experience many major milestones in healthcare innovation, and I share this accomplishment with all women in STEM [science, technology, engineering, and math], especially those I have been privileged to work alongside, who are helping pave the way for future generations.”
Since 2007, HBA has inducted a new class of Luminaries each year as part of the Woman of the Year event. To qualify as a Luminary, a woman must have more than 20 years of relevant professional experience, during which time she must make a significant impact on the healthcare industry, demonstrate leadership among colleagues, and serve as a role model and mentor to other women in healthcare. A Luminary must exemplify transformative female leadership and prioritize assisting other women in furthering their careers.
“I feel incredibly fortunate to work with Dr. Eisenberg and have learned a great deal about leadership and the important role of women in the sciences,” said Megann Vaughn Watters, vice president of corporate development, licensing, and ventures at Labcorp. “Her career accomplishments are inspirational and her knowledge unparalleled, but equally impactful are the support and advocacy she provides to others, especially women. Dr. Eisenberg is always approachable and generous with her time, much of which is spent providing advice to others. It’s easy to feel overwhelmed as a working woman with young children, but Dr. Eisenberg fosters a compassionate environment that gives her team the flexibility and support necessary to balance work with life, be innovative, and achieve goals.”
A molecular biologist by training, Dr. Eisenberg was a member of the team responsible for commercializing PCR testing in the 1990s, making large-scale testing possible. Over the last year, she has led the effort at Labcorp and across the industry to use that same technology to make high-quality testing for COVID-19 broadly available. She is highly regarded within the industry and leads by example in all that she accomplishes. For decades, she has been instrumental in developing innovations in diagnostics and patient care, improving the health and lives of people around the globe.
Dr. Eisenberg will be honored alongside other Luminaries on May 6 during the virtual Woman of the Year event.
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives. With over 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.0 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to recognition and reputation of the Company. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the COVID-19 pandemic and its impact on our business and financial condition as well as general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, the effect of public opinion on the Company’s reputation, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, the number of revenue days in a financial period, personnel costs, and the effect of exchange rate fluctuations, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks, and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.
# # #